ArticleBritish journal of cancer2023
Pathological complete response, category change, and prognostic significance of HER2-low breast cancer receiving neoadjuvant treatment: a multicenter analysis of 2489 cases.
Article in British journal of cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Pathologic response rates in HER2-low versus HER2-zero early breast cancer patients receiving neoadjuvant therapy: a systematic review and meta-analysis.Breast cancer research : BCR · 2025Pooled it
- HER2-Low Versus HER2-Zero Breast Cancer in the Neoadjuvant Setting: Pathological Complete Response and Exploratory Survival Outcomes in a Single-Center Cohort.Medicina (Kaunas, Lithuania) · 2026Article
- HER2-Low Breast Cancer: Biological Framework and Determinants of HER2 Instability.Medicina (Kaunas, Lithuania) · 2026Review
- Dynamics of HER2 status following neoadjuvant systemic therapy in breast cancer: a large single-center cohort analysis.Therapeutic advances in medical oncology · 2026Article
- Changes in HER2, ER, PR, and Ki-67 in HER2-Negative Breast Cancer After Neoadjuvant Chemotherapy: A Case-Control Study.Current oncology (Toronto, Ont.) · 2025Article
- Bibliometric analysis of global research on breast cancer with HER2-low expression.Discover oncology · 2025Article
- Differences in survival outcomes between HER2-low and HER2-zero breast cancer across heterogeneous HR expression patterns: a real-world study.World journal of surgical oncology · 2025Article
- Distinguishing Low Expression Levels of Human Epidermal Growth Factor Receptor 2 in Breast Cancer: Insights from Qualitative and Quantitative Magnetic Resonance Imaging Analysis.Tomography (Ann Arbor, Mich.) · 2025Article
- ER + HER2- early-stage breast cancer: association of HER2 expression, tumor characteristics, and outcomes.Breast cancer research and treatment · 2025Article
- Prognostic significance of HER2-low and HER2-zero status before and after neoadjuvant chemotherapy in patients with HER2-negative breast cancer.Therapeutic advances in medical oncology · 2025Article
- Unveiling the traits of HER2-low breast cancer: a comparative analysis of IHC1+ vs IHC2+/ISH-negative subgroups - insights from a 3-year cohort study.Frontiers in oncology · 2025Article
- Molecular Basis of Breast Tumor Heterogeneity.Advances in experimental medicine and biology · 2025Review
- Clinicopathological and molecular significance of HER2-low expression in Asian women with triple-negative breast cancer.Therapeutic advances in medical oncology · 2025Article
- HER2-low status improves prognosis prediction in breast cancer patients receiving neoadjuvant treatment: A comparison of pathological stage, modified CPS+EG scoring system, and Neo-Bioscore.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2024Article
- Genomic landscape of circulating tumor DNA in HER2-low metastatic breast cancer.Signal transduction and targeted therapy · 2024Article
- Patient characteristics and treatment patterns of patients with locally advanced or metastatic HER2-low breast cancer, a single site descriptive study.Breast cancer research and treatment · 2024Article
- Clinical outcomes of early-stage triple-negative breast cancer after neoadjuvant chemotherapy according to HER2-low status☆.ESMO open · 2024Article
- Impact of the CPS-EG score as a new prognostic biomarker in triple-negative breast cancer patients who received neoadjuvant chemotherapy.BMC cancer · 2024Article
- Unveiling the mysteries of HER2-low expression in breast cancer: pathological response, prognosis, and expression level alterations.World journal of surgical oncology · 2024Article
- Review
Corrections and comments
- Commented on by
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHER2-low breast cancers (BC) show a good response to novel anti-HER2 antibody-drug conjugates (ADCs) in advanced setting. Nevertheless, little is known about the response, category change, and prognosis of HER2-low BC receiving neoadjuvant treatment (NAT).
methodsConsecutive invasive BC patients who underwent ≥ 4 cycles of NAT and surgery from January 2009 to December 2020 were retrospectively reviewed. HER2-low was defined as IHC 1+ or 2+ and FISH negative. Concordance rates of HER2 and other biomarkers were analyzed by Kappa test. Kaplan-Meier analysis and Cox regression were used to assess the recurrence-free interval (RFI) and overall survival (OS).
resultsA total of 2489 patients were included, of whom 1023 (41.1%) had HER2-low tumors. HER2-low patients had a higher ER positivity rate than HER2-0 patients (78.5% vs. 63.6%, P < 0.001), and a similar breast pathological complete response (pCR) rate (20.6% vs. 21.8%, P = 0.617). Among non-pCR cases, 39.5% of HER2-0 tumors changed to HER2-low, and 14.3% of HER2-low tumors changed to HER2-0 after NAT. Low concordance rates of HER2-low status were found in both ER-positive (Kappa = 0.368) and ER-negative (Kappa = 0.444) patients. Primary HER2-low patients had a significantly better RFI than HER2-0 patients (P = 0.014), especially among ER-positive subset (P = 0.016). Moreover, HER2-low category change was associated with RFI in ER-positive subset (adjusted P = 0.043).
conclusionsCompared with HER2-0 patients, HER2-low patients had a high proportion of ER-positive tumor and a similar pCR rate, which were related with better prognosis, especially in residual cases after NAT. A remarkable instability of HER2-low status was found between the primary and residual tumor, indicating re-testing HER2 status after NAT in the new era of anti-HER2 ADCs therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.